David Grainger

464 total citations
18 papers, 300 citations indexed

About

David Grainger is a scholar working on Economics and Econometrics, General Health Professions and Psychiatry and Mental health. According to data from OpenAlex, David Grainger has authored 18 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Economics and Econometrics, 4 papers in General Health Professions and 4 papers in Psychiatry and Mental health. Recurrent topics in David Grainger's work include Health Systems, Economic Evaluations, Quality of Life (13 papers), Pharmaceutical Economics and Policy (7 papers) and Schizophrenia research and treatment (4 papers). David Grainger is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (13 papers), Pharmaceutical Economics and Policy (7 papers) and Schizophrenia research and treatment (4 papers). David Grainger collaborates with scholars based in United States, United Kingdom and Australia. David Grainger's co-authors include K Downs, Paul Trueman, Josephine Mauskopf, P. Joseph Gibson, Josie Messina, Scott W. Andersen, John J. McGrath, A.M. Crawford, Timothy Lambert and Nicholas A Keks and has published in prestigious journals such as Journal of Clinical Oncology, Schizophrenia Bulletin and Schizophrenia Research.

In The Last Decade

David Grainger

18 papers receiving 281 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Grainger United States 10 165 126 64 44 32 18 300
Krista Tromp Netherlands 9 72 0.4× 93 0.7× 46 0.7× 14 0.3× 6 0.2× 14 245
Dee Lin United States 10 35 0.2× 184 1.5× 20 0.3× 62 1.4× 17 0.5× 45 284
Kirstin Borgerson Canada 8 57 0.3× 12 0.1× 90 1.4× 28 0.6× 6 0.2× 15 221
Corinna Porteri Italy 11 60 0.4× 83 0.7× 89 1.4× 24 0.5× 2 0.1× 29 322
Jennifer C. Samp United States 11 29 0.2× 68 0.5× 16 0.3× 14 0.3× 46 1.4× 28 320
Magali Coldefy France 10 35 0.2× 73 0.6× 120 1.9× 14 0.3× 6 0.2× 40 243
Charles J. Dougherty United States 11 96 0.6× 19 0.2× 147 2.3× 7 0.2× 3 0.1× 36 325
Michael J. Witkin United States 9 47 0.3× 52 0.4× 108 1.7× 27 0.6× 4 0.1× 37 351
Jennifer Priaulx United Kingdom 9 26 0.2× 107 0.8× 23 0.4× 3 0.1× 7 0.2× 12 265
M Mason United States 7 21 0.1× 94 0.7× 79 1.2× 16 0.4× 5 0.2× 13 327

Countries citing papers authored by David Grainger

Since Specialization
Citations

This map shows the geographic impact of David Grainger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Grainger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Grainger more than expected).

Fields of papers citing papers by David Grainger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Grainger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Grainger. The network helps show where David Grainger may publish in the future.

Co-authorship network of co-authors of David Grainger

This figure shows the co-authorship network connecting the top 25 collaborators of David Grainger. A scholar is included among the top collaborators of David Grainger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Grainger. David Grainger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Fox, Nathan A., et al.. (2022). The Value of Vaccines: A Tale of Two Parts. Vaccines. 10(12). 2057–2057. 3 indexed citations
2.
3.
Paddock, Silvia, et al.. (2017). Dynamic value assessments in oncology supported by the PACE Continuous Innovation Indicators. Future Oncology. 13(25). 2253–2264. 1 indexed citations
4.
Wale, Janet, et al.. (2016). Moving beyond the rhetoric of patient input in health technology assessment deliberations. Australian Health Review. 41(2). 170–170. 15 indexed citations
5.
Mueller, Debjani, Iñaki Gutiérrez‐Ibarluzea, Tara Schuller, et al.. (2016). CAPACITY BUILDING IN AGENCIES FOR EFFICIENT AND EFFECTIVE HEALTH TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care. 32(4). 292–299. 10 indexed citations
6.
Paddock, Silvia, et al.. (2015). The PACE continuous innovation Indicators: A flexible tool to evaluate progress in cancer treatments.. Journal of Clinical Oncology. 33(15_suppl). e17783–e17783. 1 indexed citations
7.
DeLozier, Amy M., et al.. (2013). Issues In The Selection Of Comparators For Regulatory And Hta Submissions. Value in Health. 16(3). A3–A4. 1 indexed citations
8.
Mauskopf, Josephine, Costel Chirila, Kristina S. Boye, et al.. (2012). RELATIONSHIP BETWEEN FINANCIAL IMPACT AND COVERAGE OF DRUGS IN AUSTRALIA. International Journal of Technology Assessment in Health Care. 29(1). 92–100. 35 indexed citations
9.
10.
11.
Mauskopf, Josephine, et al.. (2011). PHP64 THE RELATIONSHIP BETWEEN FINANCIAL IMPACT AND THE LIKELIHOOD OF DRUG REIMBURSEMENT IN THE AUSTRALIAN HEALTH CARE SYSTEM. Value in Health. 14(3). A22–A23. 1 indexed citations
12.
Berger, Marc L. & David Grainger. (2010). Comparative Effectiveness Research. PharmacoEconomics. 28(10). 915–922. 10 indexed citations
13.
Trueman, Paul, David Grainger, & K Downs. (2010). Coverage with Evidence Development: Applications and issues. International Journal of Technology Assessment in Health Care. 26(1). 79–85. 66 indexed citations
14.
Gureje, Oye, Nicholas A Keks, David Grainger, et al.. (2003). Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophrenia Research. 61(2-3). 303–314. 70 indexed citations
15.
Mauskopf, Josephine, et al.. (2002). Estimating the Costs and Benefits of New Drug Therapies: Atypical Antipsychotic Drugs for Schizophrenia. Schizophrenia Bulletin. 28(4). 619–635. 20 indexed citations
16.
Mauskopf, Josephine, et al.. (1999). Annual health outcomes and treatment costs for schizophrenia populations.. PubMed. 60 Suppl 19. 14–9; discussion 20. 29 indexed citations
17.
Grainger, David, et al.. (1998). Olanzapine versus risperidone in the treatment of schizophrenia and related psychotic disorders. Schizophrenia Research. 29(1-2). 147–147. 7 indexed citations
18.
Grainger, David, et al.. (1998). Resource use and quality of life of olanzapine compared with risperidone; Results from an international randomized clinical trial. European Neuropsychopharmacology. 8. S225–S226. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Krista Tromp Breakdown of academic impact, for papers by Dee Lin Breakdown of academic impact, for papers by Kirstin Borgerson Breakdown of academic impact, for papers by Corinna Porteri Breakdown of academic impact, for papers by Jennifer C. Samp Breakdown of academic impact, for papers by Magali Coldefy Breakdown of academic impact, for papers by Charles J. Dougherty Breakdown of academic impact, for papers by Michael J. Witkin Breakdown of academic impact, for papers by Jennifer Priaulx Breakdown of academic impact, for papers by M Mason
Rankless by CCL
2026